Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Core Scientific Inc (CORZ) vs Sana Biotechnology Inc (SANA) Price & Performance

Core Scientific IncTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Core Scientific Inc vs Sana Biotechnology Inc — how do they compare? Core Scientific Inc trades at $20.92 (market cap $6.35B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Core Scientific Inc is far larger — about 5.6× Sana Biotechnology Inc's market cap, and Core Scientific Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.

CORZSANA
Market Cap
$6.35B$1.13B
Sector
TechnologyHealth
52-Week High
$29.16$5.92
52-Week Low
$13.55$2.68
Enterprise Value
$8.88B$1.05B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Core Scientific Inc

Core Scientific (CORZ) trades at $20.87, up 7.36% today, amid strong analyst support with 19 buy ratings and a $35.88 consensus price target. The stock shows bearish technical signals with resistance at $21, while fundamentals reveal significant losses (-$288.62M net income in 2025) despite revenue growth to $319M. Recent AMD partnership for 2.5GW data center capacity signals strategic pivot to AI infrastructure.

Outlook balances high growth potential from AI contracts against substantial cash burn and negative margins. Key risks include execution of expansion plans and profitability timeline, but institutional interest and analyst optimism suggest upside if operational targets are met.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.

The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Core Scientific Inc

Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.

Read more on CORZ

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA